Is AVBP or AXSM more undervalued in 2026?

CirclFi compares ArriVent BioPharma, Inc. (AVBP) and Axsome Therapeutics, Inc. (AXSM) using 13 institutional-grade valuation models. AVBP has a Quality of Company score of 3.6/10 while AXSM scores 6.1/10.

Which is a better buy — AVBP or AXSM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AVBP and AXSM valuations compare?

AVBP at $26.97 and AXSM at $232.83 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AVBP vs AXSM Valuation Comparison 2026 — Intrinsic Value Analysis

AVBP

Biotechnology

ArriVent BioPharma, Inc.

Quality

3.6

out of 10

Value Trap

SAFE

Price

$26.97

Last close

Models

7/13

Active

AXSM

Biotechnology

Axsome Therapeutics, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$232.83

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	AVBP Fair Value	AVBP Upside	AXSM Fair Value	AXSM Upside
Bayesian DCF	Intrinsic	$7.90	-70.7%	$79.80	-65.7%
Earnings Power Value	Intrinsic	—	—	$82.92	-55.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.38	-76.3%	$3.06	-98.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVBP vs AXSM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVBP vs AXSM — Which Stock Is More Undervalued?

AXSM scores higher with a 6.1/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ArriVent BioPharma, Inc. (AVBP) and Axsome Therapeutics, Inc. (AXSM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVBP currently trades at $26.97 with a QOC of 3.6/10, while AXSM trades at $232.83 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).